Bifogade filer
Interim Report Q1 2024
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Today, on 18 April 2024, Magle Chemoswed Holding AB (publ) has published its interim report for Q1, 2024.
Q1 2024 KEY INDICATORS
- Net sales amounted to 38.2 MSEK (38.7)
- EBITDA equalled 7.0 MSEK (7.5)
- Operating profit (EBIT) is 4.1 MSEK (4.3)
- Profit after tax amounted to 2.9 MSEK (2.9)
- Earnings per share SEK 0,3 (0,3) per share
Justin Pierce, Magle Group’s CEO commented on the results, stating, "We are pleased to report another strong quarter for Magle Group, which reflects our unwavering focus on delivering innovative solutions and superior value to our partners and patients. Despite a challenging macroeconomic environment, we have managed to maintain a solid profit margin and steady revenues. Our results are a testament to the hard work and dedication of our team, and our ability to adapt and thrive in a rapidly evolving marketplace. Looking ahead, we remain committed to investing in our core business areas, exploring new opportunities for growth, and continuing to enhance shareholder value."